ABS-0871

all catalysts(0)

nothing on the calendar yet

News(2)

• Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
  Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.
  biospace · 4d ago
• Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
  Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.
  fiercebiotech · 4d ago